New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024
DOI: 10.1016/j.bbcan.2024.189152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024. Verfasst von Zhi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Cancer Institute of Chinese Integrative Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms, Proteolysis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 119 Literaturangaben.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1) has become a crucial focus in cancer immunotherapy considering it is found in many different cells. Cancer cells enhance the suppressive impact of programmed death receptor 1 (PD-1) through elevating PD-L1 expression, which allows them to escape immune detection. Although there have been significant improvements, the effectiveness of anti-PD-1/PD-L1 treatment is still limited to a specific group of patients. An important advancement in cancer immunotherapy involves improving the PD-L1 protein degradation. This review thoroughly examined the processes by which PD-L1 breaks down, including the intracellular pathways of ubiquitination-proteasome and autophagy-lysosome. In addition, the analysis revealed changes that affect PD-L1 stability, such as phosphorylation and glycosylation. The significant consequences of these procedures on cancer immunotherapy and their potential role in innovative therapeutic approaches are emphasised. Our future efforts will focus on understanding new ways in which PD-L1 degradation is controlled and developing innovative treatments, such as proteolysis-targeting chimeras designed specifically to degrade PD-L1. It is crucial to have a thorough comprehension of these pathways in order to improve cancer immunotherapy strategies and hopefully improve therapeutic effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interventional Cancer Institute of Chinese Integrative Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China; Department of General surgery, Hubei Provincial Clinical Rese…
- Interventional Cancer Institute of Chinese Integrative Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.
- Interventional Cancer Institute of Chinese Integrative Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. Electronic address: yuanzeting@shutcm.edu.cn.
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai 200241, China. Electronic address: lli@bio.ecnu.edu.cn.
- Interventional Cancer Institute of Chinese Integrative Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. Electronic address: yinpeihao@shutcm.edu.cn.
Zitieren
APA
Li, Z., Yu, X., Yuan, Z., Li, L., & Yin, P. (2024). New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2024.189152
Vancouver
Li Z, Yu X, Yuan Z, Li L, Yin P. New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024. doi:10.1016/j.bbcan.2024.189152
BibTeX
@article{Li2024,
author = {Li, Zhi and Yu, Xi and Yuan, Zeting and Li, Lei and Yin, Peihao},
title = {New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
doi = {10.1016/j.bbcan.2024.189152}
}
EUVIMED